Holen Sie sich die Stockscreener-App
4.49
2.98%
0.13
Vorhandelsmarkt:
4.50
0.010
+0.22%
Schlusskurs vom Vortag:
$4.36
Offen:
$4.42
24-Stunden-Volumen:
54,959
Relative Volume:
0.08
Marktkapitalisierung:
$19.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.61M
KGV:
-4.9889
EPS:
-0.9
Netto-Cashflow:
$-22.91M
1W Leistung:
-0.66%
1M Leistung:
+5.90%
6M Leistung:
+3,931%
1J Leistung:
+452.62%
1-Tages-Spanne:
$4.25
$4.4991
1-Wochen-Bereich:
$4.25
$4.74
52-Wochen-Spanne:
$0.0815
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Firmenname
Bioline Rx Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
4.49 | 16.82M | 0 | -60.61M | -22.91M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-05-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-02-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-08-17 | Bestätigt | Maxim Group | Buy |
| 2015-07-27 | Bestätigt | ROTH Capital | Buy |
| 2015-06-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Bioline Rx Ltd Adr Aktie (BLRX) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
BioLineRx Ltd. Approves Key Proposals at Annual Meeting - TipRanks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment - TipRanks
BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance
BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com South Africa
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India
BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks
Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa
Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com India
BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks
BioLineRx reports promising pancreatic cancer trial data - Investing.com
JonesTrading Reaffirms Their Hold Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects - Investing.com India
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock By Investing.com - Investing.com South Africa
BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks
BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India
BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks
BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
BioLineRx stock rating cut to Hold at Jones Trading - Investing.com
BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com
H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India
BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks
BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks
BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks
Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail
BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks
Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
BLRX: Aphexda Transition Progressing - Research Tree
BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India
BioLineRx announces strategic shift with licensing deals - Investing.com
BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks
BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks
BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan
BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks
BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan
BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com
BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com
BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks
Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com
Finanzdaten der Bioline Rx Ltd Adr-Aktie (BLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):